News – Page 1116 – Endpoints News

Vivek Ramaswamy’s Myovant outlines the PhII case for its lead drug, now in a late-stage test

9 years ago

Mitsubishi Tanabe wins the race to snag the first new ALS drug OK in more than 20 years

9 years ago

Troubled Teva's successor to Copaxone just failed a big PhIII test for multiple sclerosis

9 years ago

Merck vet Robert Plenge moves to Celgene, Gritstone recruits a Genentech star and more

9 years ago

Gates Foundation fuels Achaogen’s antibody platform with $20.5M commitment; Ignyta raises $77M

9 years ago

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

9 years ago

Puma's fresh shiner, what the biotech IPO surge tells us, and the trouble with cancer R&D

9 years ago

Seattle Genetics throws in the towel on $2B Immunomedics deal, CEO and CSO axed in settlement

9 years ago

Jeremy Levin joins the biotech IPO rush, gaining $75M for Ovid’s R&D game plan

9 years ago

Stuck on FDA hold, Regulus CEO hits the exit as reorganization slashes staff at the beleaguered biotech

9 years ago

Zafgen stakes out a PhI beachhead for its next weight drug as it fights for a comeback

9 years ago

Former GSK cancer R&D chief Paoletti takes the reins at GammaDelta; Blueprint inks big Cambridge lease

9 years ago

Serial startup scientist Ronald Evans tests a new Mighty Mouse drug, making marathon runners with a pill

9 years ago

Novartis continues its blitz on NASH deals, grabbing an exclusive tie-up in race to develop cocktails

9 years ago

Two new IPOs -- upsized and over the range -- score $226M and signal a possible comeback for biotech

9 years ago

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

9 years ago

Defying the odds, Poxel plots a PhIII course for its Type 2 diabetes med and shares surge on new data

9 years ago

QuintilesIMS analysts forecast a wave of new drug approvals by '22, dominated by cancer and orphan therapies

9 years ago

Amgen backs WuXi NextCODE’s $75M B round; ImCheck bags €20 venture round for I-O work

9 years ago

Genentech cancer R&D vet Raphaël Rousseau jumps ship, joins Gritstone

9 years ago

China has a $1.45B plan to build up its biotech hubs — and officials are moving fast

9 years ago

So what’s holding back Pfizer and Gilead from the really big M&A deals we’ve all been waiting for?

9 years ago

Expansive Sosei lays out a $534M acquisition plan for the ambitious saRNA biotech MiNA

9 years ago

AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll

9 years ago

First page Previous page 1113 1114 111511161117 1118 1119 Next page Last page